Endoscopic Ultrasound Shear Wave for Liver Fibrosis in MASLD Patients: The RUMIPAMBA Trial
Recruiting
N/A
Interventional Study
Liver Steatosis
Fibrosis, Liver
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 79
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 30 (estimated)
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Currently, there is no description of the contribution of the endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) when describing liver fibrosis in patients with screening criteria of metabolic dysfunction-associated steatotic liver disease (MASLD), with absent-to-mild liver fibrosis. Similar research has been published but using vibration-controlled transient elastography (VCTE), rec…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients referred for any kind of endoscopic procedure.
* Without clinical suspicion of advanced liver fibrosis.
* Acceptance to participate in the study.
Exclusion Criteria:
* History of greater amounts of alcohol per week (140 g/week and 210 g/week for females and males re…
Contacts